Literature DB >> 21365381

Human papillomavirus vaccination in males: the state of the science.

Luis F Barroso1, Timothy Wilkin.   

Abstract

Human papillomavirus (HPV) is an extremely prevalent sexually transmitted infection that is typically acquired soon after onset of sexual activity. The burden of HPV-related malignant and nonmalignant disease is high in men and women. High-risk or oncogenic types of HPV cause cervical, vaginal, and vulvar cancer in women. These types have also been shown to cause penile cancer in men and a substantial proportion of oropharyngeal and anal malignancy in men and women. Low-risk types of HPV cause anogenital warts. Prevention of penile, anal, and oropharyngeal cancers and anogenital warts represents potential benefits of the HPV vaccine in men. This review focuses on HPV disease in men, existing data on HPV vaccination in men, and various factors associated with the decision to vaccinate boys and young men, as well as the timing of vaccination.

Entities:  

Year:  2011        PMID: 21365381     DOI: 10.1007/s11908-010-0163-7

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  42 in total

1.  Multiple human papillomavirus types appear to be a feature of anal not cervical intra-epithelial neoplasia.

Authors:  Justin Stebbing; Simon Portsmouth; Paul Fox; Cathryn Brock; Mark Bower
Journal:  AIDS       Date:  2003-11-07       Impact factor: 4.177

2.  Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men.

Authors:  J M Palefsky; E A Holly; M L Ralston; N Jay
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

3.  Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men.

Authors:  Timothy Wilkin; Jeannette Y Lee; Shelly Y Lensing; Elizabeth A Stier; Stephen E Goldstone; J Michael Berry; Naomi Jay; David Aboulafia; David L Cohn; Mark H Einstein; Alfred Saah; Ronald T Mitsuyasu; Joel M Palefsky
Journal:  J Infect Dis       Date:  2010-10-15       Impact factor: 5.226

4.  The global health burden of infection-associated cancers in the year 2002.

Authors:  Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

5.  Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

Authors:  Lieven Annemans; Vanessa Rémy; James Oyee; Nathalie Largeron
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

6.  Perianal Bowen's disease and associated malignancies. Results of a survey.

Authors:  T E Marfing; M E Abel; D M Gallagher
Journal:  Dis Colon Rectum       Date:  1987-10       Impact factor: 4.585

7.  Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

Authors:  Keith S Reisinger; Stan L Block; Eduardo Lazcano-Ponce; Rudiwilai Samakoses; Mark T Esser; Joanne Erick; Derek Puchalski; Katherine E D Giacoletti; Heather L Sings; Suzanne Lukac; Frances B Alvarez; Eliav Barr
Journal:  Pediatr Infect Dis J       Date:  2007-03       Impact factor: 2.129

8.  The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States.

Authors:  Anna R Giuliano; Eduardo Lazcano-Ponce; Luisa L Villa; Roberto Flores; Jorge Salmeron; Ji-Hyun Lee; Mary R Papenfuss; Martha Abrahamsen; Emily Jolles; Carrie M Nielson; Maria Luisa Baggio; Roberto Silva; Manuel Quiterio
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

9.  The psychosocial impact of human papillomavirus infection: implications for health care providers.

Authors:  P Clarke; C Ebel; D N Catotti; S Stewart
Journal:  Int J STD AIDS       Date:  1996 May-Jun       Impact factor: 1.359

10.  Human papillomavirus prevalence and type distribution in male anogenital sites and semen.

Authors:  Carrie M Nielson; Roberto Flores; Robin B Harris; Martha Abrahamsen; Mary R Papenfuss; Eileen F Dunne; Lauri E Markowitz; Anna R Giuliano
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-06       Impact factor: 4.254

View more
  9 in total

1.  Anal cancer - a review.

Authors:  Sajad Ahmad Salati; Azzam Al Kadi
Journal:  Int J Health Sci (Qassim)       Date:  2012-06

2.  [Urethral condyloma in a patient with neurogenic bladder dysfunction: a therapeutic challenge].

Authors:  P Bartel; K Göcking; J Pannek
Journal:  Urologe A       Date:  2013-01       Impact factor: 0.639

Review 3.  Penile cancer: current therapy and future directions.

Authors:  G Sonpavde; L C Pagliaro; C Buonerba; T B Dorff; R J Lee; G Di Lorenzo
Journal:  Ann Oncol       Date:  2013-01-04       Impact factor: 32.976

Review 4.  Human papilloma virus (HPV) vaccination in childhood: challenges and perspectives.

Authors:  I Mammas; F Maher; M Theodoridou; D Spandidos
Journal:  Hippokratia       Date:  2011-10       Impact factor: 0.471

5.  The sexual ethics of HPV vaccination for boys.

Authors:  Jeroen Luyten; Bart Engelen; Philippe Beutels
Journal:  HEC Forum       Date:  2014-03

6.  Managing uncertainty: healthcare professionals' meanings regarding the HPV vaccine.

Authors:  Irina Todorova; Anna Alexandrova-Karamanova; Yulia Panayotova; Elitsa Dimitrova; Tatyana Kotzeva
Journal:  Int J Behav Med       Date:  2014-02

7.  Attitudes surrounding implementation of the HPV vaccine for males among primary care providers serving large minority populations.

Authors:  Abraham Aragones; Denise Bruno; Francesca Gany
Journal:  J Health Care Poor Underserved       Date:  2013-05

8.  Human papillomavirus-associated cancers: a survey on otorhinolaryngologists' knowledge and attitudes on prevention.

Authors:  A Odone; S Visciarelli; T Lalic; F Pezzetti; F Spagnoli; C Pasquarella; G Ferrari; C Signorelli
Journal:  Acta Otorhinolaryngol Ital       Date:  2015-12       Impact factor: 2.124

9.  Genital Epstein Barr Virus is associated with higher prevalence and persistence of anal human papillomavirus in HIV-infected men on antiretroviral therapy.

Authors:  Sara Gianella; Christine C Ginocchio; Eric S Daar; Michael P Dube; Sheldon R Morris
Journal:  BMC Infect Dis       Date:  2016-01-25       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.